July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Episcleral sustained ocular delivery of bromfenac and brinzolamide
Author Affiliations & Notes
  • Jacklyn H Salmon
    Clinical Sciences, North Carolina State University, Raleigh, North Carolina, United States
  • Santhi Abbaraju
    Symmetry Biosciences, Research Triangle Park, North Carolina, United States
  • Shadia Hanna
    Origin Bioanalytical Laboratory, Inc., Rancho Cordova, California, United States
  • Lee Hamm
    Origin Bioanalytical Laboratory, Inc., Rancho Cordova, California, United States
  • Rasidul Amin
    Symmetry Biosciences, Research Triangle Park, North Carolina, United States
  • David Culp
    Powered Research, LLC, Research Triangle Park, North Carolina, United States
  • Brian C Gilger
    Clinical Sciences, North Carolina State University, Raleigh, North Carolina, United States
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 5687. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jacklyn H Salmon, Santhi Abbaraju, Shadia Hanna, Lee Hamm, Rasidul Amin, David Culp, Brian C Gilger; Episcleral sustained ocular delivery of bromfenac and brinzolamide. Invest. Ophthalmol. Vis. Sci. 2018;59(9):5687.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Most polymer drug delivery systems induce ocular inflammation and have limited duration of drug release, especially when delivered episclerally. The purpose of this study was to evaluate the in vitro release, tolerability, ocular drug distribution, and pharmacodynamics of bromfenac and brinzolamide released from silicone matrix implants in the episcleral space.

Methods : In vitro release in phosphate buffered saline (7.4 pH, 37C) of low dose (12 mm x 2 mm; 7.74 mg total drug) and high dose (20 mm x 2 mm; 12.18 mg total drug) silicone matrix implants (30% bromfenac or brinzolamide by weight) for 84 days was measured by HPLC. New Zealand White rabbits had either a blank silicone implant (n=2 eyes), or a low or high dose bromfenac or brinzolamide implant placed episclerally (n=8 eyes each). Ocular inflammatory scoring (modified Hackett-McDonald) and intraocular pressure (IOP) (TonoVet) were measured at 0, 1-7, 10,14, 21, and 28 days after implantation. Tissues were collected at either 7 or 28 days, and eyes were immediately frozen for drug analysis or fixed in Davidson's solution and processed for histopathology.

Results : In vitro release of both bromfenac and brinzolamide revealed an initial burst of drug release followed by a steady sustained release, with an estimated 12-month release profile. Both high and low dose implants were very well tolerated with only mild conjunctival hyperemia that resolved by 7-10 days. Eyes with implants releasing bromfenac had lower inflammatory scores than those with brinzolamide or blank implants, however, the differences were not significant. Eyes with brinzolamide implants had significantly lower IOP (mean reduction of between -4.5+/-0.4 and -4.9+/-0.5 [SEM]) in a dose dependent manner than those with bromfenac or control on days 3-28 after implantation (P<0.03). Tissue drug levels were commensurate with dose of implant. Histopathology revealed focal mononuclear infiltrates around the implant site at day 7 and mild fibrosis at day 28, but no evidence of intraocular damage or toxicity.

Conclusions : Episcleral silicone matrix implants that release bromfenac or brinzolamide were exremely well tolerated and provided sustained drug levels and therapeutic effect for greater than 28 days with an estimated duration of delivery of greater than 12 months.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×